Apellis Pharmaceuticals Inc (APLS)

$19.73 -0.37 (-1.84%)
Market Cap 2.54B
Revenue (ttm) 781.37M
Net Income (ttm) -197.88M
EPS (ttm) N/A
PE Ratio 63.90
Forward PE 79.59
Profit Margin -25.32%
Debt to Equity Ratio 1.13
Volume 2,159,400
Avg Vol 2,687,390
Day's Range N/A - N/A
Shares Out 126.53M
Stochastic %K 50%
Beta 0.70
Analysts Sell
Price Target $35.39

Company Profile

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproli...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 977 5700
Website: apellis.com
Address:
100 Fifth Avenue, Waltham, United States
scott52
scott52 Nov. 18 at 5:17 PM
$APLS Just passing through but thought I would just say: FUCK YOU, CEDRIC! That's it. Thanks for letting me express my opinion. Have a nice day.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 15 at 4:54 PM
All new commercial-stage oncology focused bios since 1/1/2020 with current market caps ranging from ~$1 to $6B continue to trade at meaningfully lower revenue multiples than their non-oncology peers, on average by 50% per the attached analysis. The attachment lists the relevant valuation related data points of all new commercial-stage oncology & non-oncology focused bios since 1/1/2020 (with market caps north of ~$1B ) ​For perspective, every single peer non-oncology focused bio since 1/1/2020 trades at higher revenue multiples than $IOVA & $SNDX . Even $ARDX & $PHAT trade at higher multiples in spite of materially shorter patent lives IBRX does as well but we understand IBRX projections are subject to pipeline wins where SNDX & IOVA are not. ​In non-oncology, $APLS & SLNO trade at lower multiples versus the majority of their peers This is not investment advice. The raw data is provided & sourced so we encourage investors to verify the attached comparisons for themselves.
5 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Nov. 14 at 8:33 PM
$APLS Deals are being cut everywhere-look at $CDTX today. Merck BO for $9B. The Board needs to cut this thing loose.
0 · Reply
The_Fact_ster
The_Fact_ster Nov. 14 at 5:14 PM
$APLS so what's happening today is everyone is going back to their list of M&A targets from 2024 and 2025, and realizing that every single other company other than APLS has been bought at this point.
1 · Reply
The_Fact_ster
The_Fact_ster Nov. 14 at 4:10 PM
$APLS while I still think management is grossly bad at commercializing a good drug here, as long as M&A stays hot in the sector this is a good value in the <25 range. Someone is eventually going to come knocking on Cedric's office door, and news will leak that this occurred. Doesn't mean Cedric is going to be smart enough to take it, but it will happen.
0 · Reply
scott52
scott52 Nov. 13 at 2:24 AM
$APLS The moves, detailed in internal emails sent Tuesday and viewed by STAT, come as the pharmaceutical giant (Abbve) is moving away from small-molecule drugs, which include pills, and investing more in injectable therapies and complex genetic medicines. https://www.statnews.com/2025/11/12/abbvie-calico-layoffs/ If only we knew where to find an undervalued stock with a best in class injectable therapy. If you guys find such a company, lemme know.
0 · Reply
4Reel
4Reel Nov. 12 at 5:28 PM
$APLS great 5 yr data on the GALE study for SYFOVRE again reported today. Delayed move up coming over the next month. 25 plus imo. I would think this is accumulation zone before the next pumo up
0 · Reply
Longboardsoul
Longboardsoul Nov. 12 at 5:16 PM
$APLS will this go up once the layoffs are announced?
1 · Reply
Count_Von_Count
Count_Von_Count Nov. 11 at 5:22 PM
$APLS Starter
2 · Reply
hdastoor
hdastoor Nov. 11 at 2:49 AM
$APLS at the American society of nephrology conference this drug proved it's superiority over Iptacopan for treatment of C3G and IC MPGN. Itnis also approved in adolescents and for kidney transplant patients ... And it's 40% cheaper than Iptacopan... They just have to execute a winning strategy now
2 · Reply
Latest News on APLS
No data available.
scott52
scott52 Nov. 18 at 5:17 PM
$APLS Just passing through but thought I would just say: FUCK YOU, CEDRIC! That's it. Thanks for letting me express my opinion. Have a nice day.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 15 at 4:54 PM
All new commercial-stage oncology focused bios since 1/1/2020 with current market caps ranging from ~$1 to $6B continue to trade at meaningfully lower revenue multiples than their non-oncology peers, on average by 50% per the attached analysis. The attachment lists the relevant valuation related data points of all new commercial-stage oncology & non-oncology focused bios since 1/1/2020 (with market caps north of ~$1B ) ​For perspective, every single peer non-oncology focused bio since 1/1/2020 trades at higher revenue multiples than $IOVA & $SNDX . Even $ARDX & $PHAT trade at higher multiples in spite of materially shorter patent lives IBRX does as well but we understand IBRX projections are subject to pipeline wins where SNDX & IOVA are not. ​In non-oncology, $APLS & SLNO trade at lower multiples versus the majority of their peers This is not investment advice. The raw data is provided & sourced so we encourage investors to verify the attached comparisons for themselves.
5 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Nov. 14 at 8:33 PM
$APLS Deals are being cut everywhere-look at $CDTX today. Merck BO for $9B. The Board needs to cut this thing loose.
0 · Reply
The_Fact_ster
The_Fact_ster Nov. 14 at 5:14 PM
$APLS so what's happening today is everyone is going back to their list of M&A targets from 2024 and 2025, and realizing that every single other company other than APLS has been bought at this point.
1 · Reply
The_Fact_ster
The_Fact_ster Nov. 14 at 4:10 PM
$APLS while I still think management is grossly bad at commercializing a good drug here, as long as M&A stays hot in the sector this is a good value in the <25 range. Someone is eventually going to come knocking on Cedric's office door, and news will leak that this occurred. Doesn't mean Cedric is going to be smart enough to take it, but it will happen.
0 · Reply
scott52
scott52 Nov. 13 at 2:24 AM
$APLS The moves, detailed in internal emails sent Tuesday and viewed by STAT, come as the pharmaceutical giant (Abbve) is moving away from small-molecule drugs, which include pills, and investing more in injectable therapies and complex genetic medicines. https://www.statnews.com/2025/11/12/abbvie-calico-layoffs/ If only we knew where to find an undervalued stock with a best in class injectable therapy. If you guys find such a company, lemme know.
0 · Reply
4Reel
4Reel Nov. 12 at 5:28 PM
$APLS great 5 yr data on the GALE study for SYFOVRE again reported today. Delayed move up coming over the next month. 25 plus imo. I would think this is accumulation zone before the next pumo up
0 · Reply
Longboardsoul
Longboardsoul Nov. 12 at 5:16 PM
$APLS will this go up once the layoffs are announced?
1 · Reply
Count_Von_Count
Count_Von_Count Nov. 11 at 5:22 PM
$APLS Starter
2 · Reply
hdastoor
hdastoor Nov. 11 at 2:49 AM
$APLS at the American society of nephrology conference this drug proved it's superiority over Iptacopan for treatment of C3G and IC MPGN. Itnis also approved in adolescents and for kidney transplant patients ... And it's 40% cheaper than Iptacopan... They just have to execute a winning strategy now
2 · Reply
buylowandwait
buylowandwait Nov. 7 at 8:50 PM
$APLS Significant increase by Wellington Management
2 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 1:26 PM
Wolfe Research has updated their rating for Apellis Pharmaceuticals ( $APLS ) to Peer Perform.
0 · Reply
JarvisFlow
JarvisFlow Nov. 5 at 7:49 PM
JP Morgan has updated their rating for Apellis Pharmaceuticals ( $APLS ) to Overweight with a price target of 36.
0 · Reply
scott52
scott52 Nov. 5 at 5:24 PM
$APLS The only real catalyst on the horizon is a 50bp rate cut when it becomes clear that we're in a recession. Many states are already in a recession. Texas and Florida are holding down the fort for the whole country. I'm not sure how much longer that can last. "The U.S. economy is very close to falling into a damaging contraction — and many states are already experiencing a recession, according to Mark Zandi, chief economist at Moody’s Analytics. Zandi estimates that 22 states plus the District of Columbia are now experiencing persistent economic weakness and job losses that are likely to continue. Another 13 states are treading water, he noted. The overall picture is one of a weak U.S. economy that is vulnerable to being pushed into a ditch by a strong wind. “The economy is still not in recession, but the risks are very high. We’re on the precipice,” Zandi said in an interview with MarketWatch."
0 · Reply
The_Fact_ster
The_Fact_ster Nov. 5 at 3:23 PM
$APLS Well Cedric did his best in taking care of that brief moment of joy.
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Nov. 4 at 5:33 PM
$APLS sucking the life out of this... I hope they all circle jerk each other.
1 · Reply
OpheliaPaine
OpheliaPaine Nov. 3 at 8:24 PM
$APLS Agree 100 percent. If ever there were a company that would benefit from the involvement of an activist investor, APLS is it.
0 · Reply
Rabinovich
Rabinovich Nov. 3 at 6:23 PM
$APLS This has been shorted to death anyways and the QURE news is completely devastating for the entire sector. To add insult to injury the management are totally incompetent to run a commercial stage bio and too greedy to sell. Fun times.
0 · Reply
Rabinovich
Rabinovich Nov. 3 at 6:09 PM
$APLS Total assholes.
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Nov. 3 at 6:01 PM
$APLS BEWARE! Dead money.
0 · Reply
JarvisFlow
JarvisFlow Nov. 3 at 5:58 PM
Mizuho has adjusted their stance on Apellis Pharmaceuticals ( $APLS ), setting the rating to Neutral with a target price of 24 → 19.
1 · Reply
monoksop
monoksop Nov. 3 at 12:24 AM
$APLS I honestly can’t see how they get to a loss in 2027—would have to have Syfovre revenue stay flat from here on out, and if they have a profit on the books for 2028, that has to involve either Syfovre growth or C3G being worth more than $200M/year. As far as where I’m at—modelling 2% QoQ Syfovre growth from Q1 2026 onwards with room for misses along the way. Likely to remain flat for 4Q 2025, not much we can do there, if they print in the mid-$150M range, that would be a huge win. This model assumes 16% penetration of the C3G/IC-MPGN market (or roughly 800 patients on-drug) by YE 2028, and 1 flat quarter per year for Syfovre:
2 · Reply